From GlobeNewswire: 2025-03-31 07:32:00

SAB BIO reported financial results for Q4 2024 and the full fiscal year, highlighting progress in developing human anti-thymocyte immunoglobulin for type 1 diabetes. Recent positive topline data for SAB-142 supports its potential as a disease-modifying therapy for T1D. The company aims to advance development and begin a Phase 2b trial in 2025.

Recent pipeline developments include positive Phase 1 trial data for SAB-142, a human hIgG for preventing type 1 diabetes onset or progression. With successful results, SAB-142 is set to enter Phase 2b clinical development later in 2025. The company hosted a virtual R&D event to discuss these findings with key opinion leaders.

In 2024, SAB BIO made corporate updates, including the establishment of a clinical advisory board and appointing a new Chief Financial Officer and Board members. Financially, the company reported $20.8 million in cash at the end of 2024, with R&D expenses totalling $30.3 million and a net loss of $34.1 million for the year.

SAB BIO is a clinical-stage biopharmaceutical company focused on developing high-potency immunoglobulins to treat immune and autoimmune disorders. Using innovative technology, the company aims to address unmet needs in human diseases. SAB-142, targeting T1D, represents a disease-modifying therapeutic approach that could change treatment paradigms.



Read more at GlobeNewswire:: SAB BIO Reports Full Year 2024 Operating and Financial